AbbVie hikes full|year earnings guidance as Humira sales top ...

AbbVie hikes full-year earnings guidance as Humira sales top ...

For the fiscal Q2, AbbVie reported adjusted EPS of $2.65, slightly below analyst expectations of $2.70. Net revenue for the quarter was $14.46 ...

AbbVie's Skyrizi snatches sales crown from Humira as company lifts ...

The duo's strong showing prompted AbbVie to again crank up its full-year earnings-per-share outlook to $10.90 to $10.94, up from its second- ...

StreetInsider.com on LinkedIn: AbbVie $ABBV hikes full-year ...

AbbVie $ABBV hikes full-year earnings guidance as Humira sales top estimates https://loom.ly/zZonEEA.

AbbVie Reports Third-Quarter 2024 Financial Results

Global Humira net revenues of $2.227 billion decreased 37.2 percent on a reported basis, or 36.5 percent on an operational basis. U.S. Humira ...

Streetinsider.com on X: "AbbVie $ABBV hikes full-year earnings ...

AbbVie $ABBV hikes full-year earnings guidance as Humira sales top estimates https://t.co/Ge0V9R9vQF.

AbbVie Is About To Have A New Golden Goose As Humira Sales ...

AbbVie Hikes Its Earnings Outlook. AbbVie raised its earnings outlook for the year. The pharma company now expects to earn $10.71 to $10.91 ...

AbbVie's immunology blockbusters make up for Humira sales drop ...

AbbVie is lifting its profit outlook and full-year 2024 guidance as its immunology blockbusters Skyrizi and Rinvoq beat quarterly revenue ...

AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidance - StreetInsider

For earnings history and earnings-related data on AbbVie (ABBV) click here. ... hikes full-year earnings guidance as Humira sales top estimates July 25, 2024 7:56 ...

AbbVie Stock Rises After Earnings Beat, Dividend Hike - Barron's

Revenue from its immunology portfolio was $7 billion, an increase of 3.9% compared to the same period last year. Sales of Humira, which treats ...

AbbVie plays it cool in the face of Humira biosimilars - Fierce Pharma

AbbVie 'comfortable' after Humira biosim launch, as CEO forecasts 'stable' sales for star med into next year ... In the first earnings stretch ...

AbbVie raises outlook as Humira again delivers earnings beat

Drugmaker AbbVie is raising its full-year earnings guidance ... sales this year, in a note to investors. ... AbbVie hikes forecast, tops Street expectations.

Two decades and $200 billion: AbbVie's Humira monopoly nears its ...

Biosimilar copies of Humira will arrive in the U.S. soon, testing both AbbVie and the market potential of knockoff biologic drugs.

AbbVie raises 2024 profit forecast on strong sales of key drugs ...

AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat ...

AbbVie Reports Third-Quarter 2023 Financial Results

AbbVie is raising its adjusted diluted EPS guidance for the full year 2023 from $10.86 - $11.06 to $11.19 - $11.23.

BIG PHARMA EARNINGS WATCH: ABBVIE AND ASTRAZENECA

AbbVie's blockbuster arthritis drug Humira, the world's top-selling drug since 2012, also beat wall street estimates, increasing sales to $5.6 ...

BIG PHARMA EARNINGS WATCH: PFIZER, ABBVIE, SANOFI, ELI ...

Pfizer raised its full-year sales guidance for ... AbbVie's blockbuster arthritis drug Humira, the world's top-selling ... Eli Lilly started 2022 with more than a ...

Drug Pricing Investigation - Document Repository

Due in large part to AbbVie's price increases,. Humira is the highest grossing drug in the United States. U.S. net revenue for Imbruvica has ...

AbbVie Inc. ($ABBV) Stock Forecast - Morpher

The hike in full-year earnings guidance was primarily driven by strong demand for one of AbbVie's key drugs, Humira, surpassing estimates. Despite a drop in ...

AbbVie raises full year profit guidance as Humira sales fall - Quartz

In its latest quarterly earning report, AbbVie raised its annual profit forecast to between $11.13 and $11.33 per share, from a previous ...

ABBV240816C00130000 (ABBV240816C00130000) Stock Price ...

AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes ... Sales of AbbVie's flagship arthritis drug Humira, once the world's top- ...